MATERIALS AND METHODS FOR PROGNOSING LUNG CANCER SURVIVAL

• US 20080176236A1
• Filed: 11/15/2007
• Published: 07/24/2008
• Est. Priority Date: 11/15/2006
• Status: Active Grant

• Current Assignee: University Health Network
• Original Assignee: University Health Network
• Inventors: Boutros, Paul, Jurisica, Igor, Lau, Suzanne, Der, Sandy, Pintilie, Melania, Shepherd, Frances A., Penn, Linda, Tsao, Ming Sound
• Granted Patent: US 8,026,055 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57423 of lung

Abstract

The invention provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups. The invention also includes kits for use in the methods of the invention.

Claims

1. A method of prognosing or classifying a subject with early stage non-small cell lung cancer, comprising the steps:

(a) determining the expression of a biomarker in a test sample from the subject, wherein the biomarker comprises one or more biomarkers as shown in Table 1;

(b) comparing the expression of the biomarker with a control,

wherein a difference in the expression of the biomarker between the control and the test sample is used to prognose or classify the subject with early stage non-small cell lung cancer into a poor survival group or a good survival group.

2. The method according to claim 1 wherein the biomarkers comprise at least 2 biomarkers as shown in Table 1.

3. The method according to claim 1, wherein the biomarkers comprise STX1A, CCR7 and HIF1A.

4. The method according to claim 1, wherein the biomarkers comprise STX1A, HIF1A, CCT3, HLA-DPB1, MAFK and RNF5.

5. The method according to claim 1, wherein the subject has stage I NSCLC.

6. The method according to claim 2, wherein the subject has stage I NSCLC.

7. The method according to claim 3, wherein the subject has stage I NSCLC.

8. The method according to claim 4, wherein the subject has stage I NSCLC.

9. The method according to claim 1, wherein the subject has stage II NSCLC.

10. The method according to claim 2, wherein the subject has stage II NSCLC.

11. The method according to claim 3, wherein the subject has stage II NSCLC.

12. The method according to claim 4, wherein the subject has stage II NSCLC.

13. A kit to prognose or classify a subject with early stage non-small cell lung cancer, comprising detection agents that can detect the expression products of biomarkers, wherein the biomarkers comprise one or more of the biomarkers as shown in Table 1.

14. The kit according to claim 13, wherein the biomarkers comprise STX1A, CCR7 and HIF1A.

15. The kit according to claim 13, wherein the biomarkers comprise STX1A, HIF1A, CCT3, HLA-DPB1, MAFK and RNF5.